New EMA product specific guidance (PSG) [BE/BA News]

posted by dshah  – India, 2024-01-17 11:12 (289 d 23:16 ago) – Posting: # 23830
Views: 1,633

Thanks SMA for sharing.

Dear all, In Azacitidine powder for suspension for injection PSG, I am having a small question.

For biowaiver it is mentioned- "Equivalent particle size distribution as demonstrated by showing average equivalence for D10, D50, D90 and span within an acceptance range of 15% for the ratio of geometric means between test and reference products (i.e., 85.00–117.64%)."
But it also mentions: "At least 3 batches of the test and reference product should be included in the comparability studies. More batches may be needed in case of higher variability of the reference product results."

So in case of higher variability in reference product result for PSD, the ratio should be limited to 85.00–117.64%?

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,279 posts in 4,889 threads, 1,657 registered users;
81 visitors (0 registered, 81 guests [including 12 identified bots]).
Forum time: 10:29 CET (Europe/Vienna)

Pharmacokinetics: one of the magic arts of divination
whereby needles are stuck into dummies in an attempt
to predict profits.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5